Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A population-based case-control study was conducted in the Henry Ford Health System (HFHS) in metropolitan Detroit to assess occupational exposures to
manganese
, copper, lead, iron, mercury and zinc as risk factors for
Parkinson's disease
(PD). Non-demented men and women 50 years of age who were receiving primary medical care at HFHS were recruited, and concurrently enrolled cases (n = 144) and controls (n = 464) were frequency-matched for sex, race and age (+/- 5 years). A risk factor questionnaire, administered by trained interviewers, inquired about every job held by each subject for 6 months from age 18 onward, including a detailed assessment of actual job tasks, tools and environment. An experienced industrial hygienist, blinded to subjects' case-control status, used these data to rate every job as exposed or not exposed to one or more of the metals of interest. Adjusting for sex, race, age and smoking status, 20 years of occupational exposure to any metal was not associated with PD. However, more than 20 years exposure to
manganese
(Odds Ratio [OR] = 10.61, 95% Confidence Interval [CI] = 1.06, 105.83) or copper (OR = 2.49, 95% CI = 1.06,5.89) was associated with PD. Occupational exposure for > 20 years to combinations of lead-copper (OR = 5.24, 95% CI = 1.59, 17.21), lead-iron (OR = 2.83, 95% CI = 1.07,7.50), and iron-copper (OR = 3.69, 95% CI = 1.40,9.71) was also associated with the disease. No association of occupational exposure to iron, mercury or zinc with PD was found. A lack of statistical power precluded analyses of metal combinations for those with a low prevalence of exposure (i.e.,
manganese
, mercury and zinc). Our findings suggest that chronic occupational exposure to
manganese
or copper, individually, or to dual combinations of lead, iron and copper, is associated with PD.
...
PMID:Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. 1038 87
Manganese
neurotoxicity has been known for more than 150 years, since Couper (1837) described a syndrome, similar to
Parkinson's disease
, in Scottish workers exposed to high levels of dust while grinding "black oxide of manganese" at a chemical industry. Since then, the syndrome has been described in several groups of highly exposed miners and other workers. A thorough review of
manganese
neurotoxicity was provided by the WHO (1981) and a recent update was written by Mergler and Baldwin (1997). From these reviews it is evident that the critical effect from
manganese
exposure is damage to the central nervous system, and that the effects, once established, are generally irreversible. Therefore, the early detection of symptoms of
manganese
neurotoxicity in populations at risk is of the utmost importance. In spite of this fact, only about a dozen studies of
manganese
exposed groups of workers have been performed using psychological test methods. These studies are briefly presented, the preponderance of proof for Mn neurotoxicity even in present industrial settings is demonstrated, the critical exposure level is briefly discussed, the test methods are evaluated, and recommendations for a test battery useful for studies of
manganese
neurotoxicity, are presented.
...
PMID:Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. 1038 93
Manganese
is an element which is required by the human body. However, as with most metals, in large amounts
manganese
can be toxic. People who suffer from severe
manganese
intoxication have symptoms similar to those of
Parkinson's disease
. Preclinical symptoms of
manganese
intoxication have recently been detected in individuals working in industries which have
manganese
dioxide dust in the air. The concentration of many toxic elements can be measured in vivo using neutron activation. A small dose of neutrons is delivered to the organ of interest, the neutrons are readily captured by the target nuclei, and the gamma rays given off can be detected outside of the body. A neutron activation analysis system is being developed to measure
manganese
concentrations in humans. The McMaster KN-accelerator supplies the neutron beam and the thermal neutron capture reaction 55Mn(n,gamma)56Mn is used. The half-life of 56Mn is 2.58 hr and thus counting can occur after irradiation. The 847 keV gamma ray given off when 56Mn decays is detected using a Nal detector. Calibration curves are made using phantoms with known concentrations of Mn. This system will be used to monitor
manganese
levels in individuals who have occupational exposure to the element. Preliminary measurements, using liver phantoms, give a minimum detectable limit for Mn in the liver of less than one part per million, which is well below normal levels.
...
PMID:The feasibility of measuring manganese concentrations in human liver using neutron activation analysis. 1038
It was observed by Couper in 1837 that
manganese
dust produces a neurological syndrome characterized by muscle weakness, tremor, bent posture, whispered speech and excess salivation. The similarity of these symptoms to those of
Parkinson's disease
were not recognized for many years. In addition to its Parkinson-like effects,
manganese
produces behavioral symptoms in humans including nervousness, hallucinations, memory loss, cognitive problems, bizarre behaviors and flight of ideas. Despite these signs and symptoms, there have been few systematic attempts to study the effects of
manganese
on behavior using animal models. The need to better understand the effects of
manganese
on behavior is becoming more important due to the potential of increased environmental exposure to
manganese
due to its use, or proposed use as a gasoline additive in a number of countries. However, there is debate as to which
manganese
compounds should receive priority for testing, what route of administration should be used in this testing, what dosing regimens should be used, what species are appropriate for behavioral testing, and what behavioral tests should be selected. Research to answer these questions is needed so that the behavioral effects of
manganese
can be described comprehensively and the mechanisms underlying these effects can be understood.
...
PMID:A brief history of the neurobehavioral toxicity of manganese: some unanswered questions. 1038 8
Parkinson's disease
(PD) is one of the major progressive neurological disorders for which no preventative or long-term effective treatment strategies are available. Epidemiologic studies have failed to identify specific environmental, dietary or lifestyle risk factors for PD except for toxic exposure to
manganese
, meperidine (Demerol, the "designer drug" version of which often contains a toxic byproduct of the synthesis, 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine [MPTP]), and some herbicides and pesticides. The search for genetic risk factors such as mutation, overexpression or underexpression of nuclear genes in DA neurons in idiopathic PD has not been successful as yet. Polymorphism in certain genes appears to be a risk factor, but there is no direct evidence for the causal relationship between polymorphism and increased risk of PD. In familial PD, mutation in the alpha-synuclein gene is associated with the disease, but a direct role of this gene in degeneration of DA neurons remains to be established. Although mutations in the Parkin gene has been associated with autosomal recessive juvenile
Parkinson's disease
, the role of this gene mutation in causing degeneration of DA neurons has not been defined. We have reported that in hereditary PD, a mutation in the alpha-synuclein gene may increase the sensitivity of DA neurons to neurotoxins. We hypothesize that, in idiopathic PD, epigenetic (mitochondria, membranes, protein modifications) rather than genetic events are primary targets which, when impaired, initiate degeneration in DA neurons, eventually leading to cell death. Although the nature of neurotoxins that cause degeneration in DA neurons in PD is not well understood, oxidative stress is one of the intermediary risk factors that could initiate and/or promote degeneration of DA neurons. Therefore, supplementation with antioxidants may prevent or reduce the rate of progression of this disease. Supplementation with multiple antioxidants at appropriate doses is essential because various types of free radicals are produced, antioxidants vary in their ability to quench different free radicals and cellular environments vary with respect to their lipid and aqueous phases. L-dihydroxyphenylalanine (L-dopa) is one of the agents used in the treatment of PD. Since L-dopa is known to produce free radicals during its normal metabolism, the combination of L-dopa with high levels of multiple antioxidants may improve the efficacy of L-dopa therapy.
...
PMID:Multiple antioxidants in the prevention and treatment of Parkinson's disease. 1051 22
Occupational exposure to specific metals (
manganese
, copper, lead, iron, mercury, zinc, aluminum and others) appears to be a risk factor for
Parkinson's disease
(PD) in some, but not all, case-control studies. These epidemiological studies are reviewed. Several methodological issues that may account for the lack of unanimity of findings are discussed, and suggestions for improved case-control methodology are offered. The study of the neurological disease outcome of workers who have had long-term, well-defined occupational exposure to one or more metals is also urged, with collaborative work including industrial hygienists, occupational toxicologists, neurologists, epidemiologists and biostatisticians. Such efforts, employing state-of-the-art case and control ascertainment and enrollment from suitable population bases, neurological diagnostic rigor and exposure assessment, will help to further define the potentially important roles played by metals in PD and other neurodegenerative disorders.
...
PMID:Occupational metal exposures and the risk of Parkinson's disease. 1054 82
Positron emission tomography (PET) with [18F] 6-fluoro-L-dopa (18F-FDOPA) was performed in three South Korean patients with parkinsonism who developed after chronic
manganese
exposure. A 51-year-old man (patient 1) suffered from masked face, marked postural tremor of hands, dystonia in the neck and the upper extremities, severe retropulsion and lateropulsion which were typical for chronic
manganese
intoxication. 18F-FDOPA scan was normal. Other two patients, a 46-year-old man (patient 2) and a 47-year-old man (patient 3), showed tremor at rest and rigidity predominantly on the right side, bradykinesia, stooped posture and postural instability; all of these were typical for
Parkinson's disease
(PD). There was reduced uptake of 18F-FDOPA in the striatum, particularly in the posterior putamen predominant on the left side, in both patient 2 and 3. From these results, patient 1 was diagnosed as pure manganism, while patient 2 and 3 were primarily as PD, because loss of nigrostriatal fibers was obvious with asymmetry of affection in the putamen. PET with 18F-FDOPA provides valuable information for differentiation between PD and manganism, although it is not clear whether development of parkinsonian symptoms in patient 2 and 3 was modified by excessive
manganese
exposure.
...
PMID:[Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure]. 1054 4
New insights into the understanding of the changes induced in the iron domain of neuromelanin (NM) upon development of
Parkinson's disease
(PD) have been gained by electron paramagnetic spectroscopy (EPR). The results of this study are compared with a previously reported variable temperature analysis of X-band EPR spectra of a NM specimen obtained from control brain tissues. The availability of high sensitivity instruments operating in the Q-band (34.4 GHz) allows us to deal with the low amounts of NM available from PD brains. The organization of iron in NM is in the form of polynuclear superparamagnetic/antiferromagnetic aggregates, but the lack of one or more signals in the EPR spectra of NM from PD suggests that the development of the pathology causes NM to decrease its ability to bind iron. Furthermore, the detection of the
Mn(II)
signal in the Q-band spectra is exploited as an additional internal probe to assess minor structural differences in iron domains of PD and control NM specimens.
...
PMID:Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. 1069 72
Free radical are highly reactive chemical species with an unpaired electron in an atomic or molecular orbital. In biological systems, the most important free radicals are superoxide anion and hydrogen peroxide; in the presence of transition metals such as iron, copper and
manganese
both these free radicals produce hydroxyl radicals. Free radicals attack proteins, nuclei acids and membranes containing large quantities of polyunsaturated fatty acids. Because of their toxicity, the organism has developed ways to deactivate them. The superoxide dismutase enzyme (SOD) catalyzes dismutation of the superoxide radical into hydrogen peroxide and oxygen hydrogen peroxide is in turn reduced to water and oxygen by peroxidase glutathione and catalase enzymes. The production of radicals in the brain is due to catecholamine metabolism such as dopamine and norepinephrine and is increased by the presence of transition metals and by a deficiency of antioxidant agents such as vitamin E. Two main groups of dementia exist in older age: the multi-infarctual dementias, caused by cerebrovascular disorders and the primary degenerative disorders such as Alzheimer, where no vascular disease is evident. Free radicals play an important role in
Parkinson's disease
, in Alzheimer's disease and in stroke. The value of SOD and CAT activity following the above mentioned degenerative diseases differ among the various studies carried out. In Alzheimer's disease, the value of SOD activity probably increases in the neuropathologically involved areas. In stroke, the SOD value does not vary either in the ischemic area or in the peri-infarctual one during the first 24 hrs after lesion, while the CAT value decreases.
...
PMID:Free radicals: important cause of pathologies refer to ageing. 1070 16
The metals iron (Fe) and
manganese
(Mn) are essential for normal functioning of the brain. This review focuses on recent developments in the literature pertaining to Fe and Mn transport. These metals are treated together because they appear to share several transport mechanisms. In addition, several neurological diseases such as Alzheimer's Disease,
Parkinson's Disease
, and Huntington's Disease are all associated with Fe mismanagement in the brain, particularly in the striatum and basal ganglia. Similarly, Mn accumulation in brain also appears to target the same brain regions. Therefore, stringent regulation of the concentration of these metals in the brain is essential. The homeostatic mechanisms for these metals must be understood in order to design neurotoxicity prevention strategies.
...
PMID:Existing and emerging mechanisms for transport of iron and manganese to the brain. 1077 72
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>